Infectious Disease Vaccines

About Glycan Therapeutics

Glycan Therapeutics is a private, pre-clinical stage biotech pioneering a new class of medicines based on glycobiology. The company's core technology platform enables the rational design of glycan-targeting molecules, including antibodies and vaccines, to modulate immune responses and disrupt disease mechanisms. Its initial pipeline focuses on oncology and infectious diseases, seeking to address limitations of current therapies. As a platform company, it operates a pre-revenue business model typical of early-stage biotechs, relying on venture funding and potential partnerships for advancement.

Therapeutic Areas